Accelerated subcutaneous nodulosis in patients with rheumatoid arthritis treated with tocilizumab: a case series

Tocilizumab is a monoclonal antibody directed against the interleukin-6 receptor, which is approved for the treatment of moderate-to-severe rheumatoid arthritis. Authors have found that it prevents lung and su...

https://ift.tt/2kJrlHv

Complexity, Variation, and the Ever-moving Cheese

No abstract available

https://ift.tt/2xBk6uo

The 2018 AAAAI Foundation Faculty Development Awardees

Publication date: Available online 2 June 2018
Source:Journal of Allergy and Clinical Immunology
Author(s): Zuhair K. Ballas




https://ift.tt/2Jv2uoK

The use of honey in cochlear implant associated wounds in pediatric patients

Publication date: August 2018
Source:International Journal of Pediatric Otorhinolaryngology, Volume 111
Author(s): Anya Costeloe, Nathan Douglas Vandjelovic, Michel Anthony Evans, Sonal S. Saraiya
IntroductionThe use of honey in wound care is becoming more common due to the proven benefit in all three phases of wound healing, as well as the antibacterial and antibiofilm properties. We present our experience using TheraHoney gel, a medical grade honey, for the successful treatment of cochlear implant associated skin breakdown.ObjectiveTo describe the role of TheraHoney gel in the management of cutaneous infection and ulceration associated with cochlear implants.MethodsThree cases of wounds treated traditionally with antibiotics, plus the addition of TheraHoney, were retrospectively reviewed. The first patient had a superficial 1 × 1 cm ulcer, the second patient had bilateral ulcers: one superficial 1.5 × 1.5 cm ulcer and the other a 1.5 × 2 cm stage III pressure ulcer with an exposed receiver stimulator, and the third patient with a 3 × 3.5 cm stage III ulcer with an exposed receiver stimulator.ResultsWith the addition of TheraHoney gel, complete wound closure was achieved at all three patients without the need for surgical reconstruction.ConclusionCutaneous infection with or without skin breakdown is a common delayed complication after cochlear implantation. We demonstrate the efficacy of adding medical grade honey in promoting healing in infected scalp pressure ulcers overlying the cochlear implant site.



https://ift.tt/2Jp65EZ

TAILORx trial finds most women with early breast cancer do not benefit from chemotherapy

Findings from the TAILORx clinical trial show chemotherapy does not benefit most women with early breast cancer. The new data, released at the 2018 ASCO annual meeting, will help inform treatment decisions for many women with early-stage breast cancer.

https://ift.tt/2HfzhZZ

Metabolic signature of squamous cell carcinoma of the head and neck: Consequences of TP53 mutation and therapeutic perspectives

Publication date: August 2018
Source:Oral Oncology, Volume 83
Author(s): Mark D. Wilkie, Andrew S. Lau, Nikolina Vlatkovic, Terence M. Jones, Mark T. Boyd
There is a pressing need to identify ways of sensitising squamous cell carcinomas of the head and neck (SCCHN) to the effects of current treatments, both from oncological and functional perspectives. Alteration to cellular metabolism is now widely considered a hallmark of the cancer phenotype; presents a potentially attractive therapeutic target in this regard; and as such has received renewed research interest in recent years. However, whilst metabolic disruption may occur to some degree in all tumours, there is undoubtedly heterogeneity and detailed study of individual tumour types is paramount if effective therapeutic strategies targeting metabolism are to be developed and effectively deployed. In this review we outline current understanding of altered tumour metabolism and how these adaptations promote tumorigenesis generally. We relate this specifically to SCCHN by focusing on several recent key studies specific to SCCHN, and by discussing the role TP53 mutation may play in this metabolic switch, given the fundamental role of this oncogenic event in SCCHN tumorigenesis. Finally, we also offer insight into the potential therapeutic implications this may have in the clinical setting and make recommendations for future study.



https://ift.tt/2xBOp4m

Risk of operating on the wrong site: how to avoid a never event

Joy C Edlin<br />May 7, 2018; 2018:bcr-2017-223704-bcr-2017-223704<br />Images in...

https://ift.tt/2J7PYwj